Last reviewed · How we verify
pneumococcal conjugate 13 valent vaccine — Competitive Intelligence Brief
marketed
Conjugate vaccine
Streptococcus pneumoniae capsular polysaccharides (13 serotypes)
Immunology / Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
pneumococcal conjugate 13 valent vaccine (pneumococcal conjugate 13 valent vaccine) — University of Siena. Pneumococcal conjugate 13-valent vaccine stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| pneumococcal conjugate 13 valent vaccine TARGET | pneumococcal conjugate 13 valent vaccine | University of Siena | marketed | Conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (13 serotypes) | |
| Prevnar 20 | pneumococcal 20-valent conjugate vaccine (PCV20) | Pfizer Inc. | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (20 serotypes) | 2021-06-08 |
| MenACWY-TT | MenACWY-TT | Pfizer | marketed | Meningococcal conjugate vaccine | ||
| NeisVac C vaccine (12mth) | NeisVac C vaccine (12mth) | University of British Columbia | marketed | Meningococcal conjugate vaccine | Neisseria meningitidis serogroup C polysaccharide capsule | |
| PCV10 full dose | PCV10 full dose | Epicentre | marketed | Pneumococcal conjugate vaccine | ||
| PedvaxHIB® | PedvaxHIB® | GlaxoSmithKline | marketed | Conjugate vaccine | Haemophilus influenzae type b polyribosylribitol phosphate (PRP) capsular polysaccharide | |
| NeisVac-C® | NeisVac-C® | Merck Sharp & Dohme LLC | marketed | Meningococcal conjugate vaccine | Neisseria meningitidis serogroup C polysaccharide capsule |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Prevnar 20 · US 8,895,024 · Composition of matter · US
- — Prevnar 20 · US 10,279,033 · Method of use · US
Sponsor landscape (Conjugate vaccine class)
- GlaxoSmithKline · 26 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 6 drugs in this class
- CanSino Biologics Inc. · 3 drugs in this class
- MCM Vaccines B.V. · 3 drugs in this class
- Beijing Minhai Biotechnology Co., Ltd · 3 drugs in this class
- Wyeth is now a wholly owned subsidiary of Pfizer · 2 drugs in this class
- PT Bio Farma · 2 drugs in this class
- LG Life Sciences · 2 drugs in this class
- Walvax Biotechnology Co., Ltd. · 2 drugs in this class
- Heinrich-Heine University, Duesseldorf · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- pneumococcal conjugate 13 valent vaccine CI watch — RSS
- pneumococcal conjugate 13 valent vaccine CI watch — Atom
- pneumococcal conjugate 13 valent vaccine CI watch — JSON
- pneumococcal conjugate 13 valent vaccine alone — RSS
- Whole Conjugate vaccine class — RSS
Cite this brief
Drug Landscape (2026). pneumococcal conjugate 13 valent vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/pneumococcal-conjugate-13-valent-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab